Sutro Biopharma (STRO)

Executive Summary

Sutro Biopharma is a clinical-stage biotechnology company leveraging its proprietary XpressCF cell-free protein synthesis platform to develop next-generation protein therapeutics, including antibody-drug conjugates (ADCs) and bispecific antibodies, primarily for oncology. The company's lead candidate, STRO-002, is a folate receptor alpha (FolRα)-targeting ADC currently in a Phase 1/2 trial for malignant neoplasms, with a primary completion date in 2027. Additionally, STRO-004, a PD-L1/VEGF bispecific antibody, is being evaluated in combination with pembrolizumab across multiple solid tumors in a Phase 1 trial initiated in late 2025. Despite some pipeline attrition, including termination of luveltamab tazevibulin studies in lung cancer and AML, Sutro maintains a focused development strategy. The company's platform enables rapid and efficient production of homogeneous protein therapeutics, which could provide competitive advantages in drug design and manufacturing. With a market capitalization of approximately $684 million and a cash position supported by partnerships, Sutro is positioned to deliver clinical proof-of-concept data that may de-risk its pipeline and potentially lead to value-inflecting milestones.

Upcoming Catalysts (preview)

• H2 2026STRO-002 Phase 1/2 interim efficacy and safety data60% success
• H1 2027Initial clinical update from STRO-004 + pembrolizumab Phase 1 trial50% success
• TBDPotential business development or partnership announcement for XpressCF platform40% success